Tempest Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Tempest Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2012 to 2023.
  • Tempest Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$10.6M, a 60.1% decline year-over-year.
  • Tempest Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$35.6M, a 16.5% decline year-over-year.
  • Tempest Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$29.2M, a 15.8% increase from 2022.
  • Tempest Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$34.6M, a 28.4% decline from 2021.
  • Tempest Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$27M, a 39.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$29.2M +$5.48M +15.8% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-19
2022 -$34.6M -$7.65M -28.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-19
2021 -$27M -$7.69M -39.8% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-22
2020 -$19.3M +$26.1M +57.5% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-29
2019 -$45.4M -$18.5M -68.9% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-29
2018 -$26.9M +$57.5M +68.1% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-11
2017 -$84.3M -$3.31M -4.09% Jan 1, 2017 Dec 31, 2017 10-K 2019-04-01
2016 -$81M -$9.01M -12.5% Jan 1, 2016 Dec 31, 2016 10-K 2018-03-15
2015 -$72M -$24.1M -50.2% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-15
2014 -$47.9M -$18.8M -64.5% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-02
2013 -$29.1M -$15.6M -115% Jan 1, 2013 Dec 31, 2013 10-K 2016-02-26
2012 -$13.5M Jan 1, 2012 Dec 31, 2012 10-K 2015-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.